GlassScriptPhysician profile
Kena Patel
NPI 1760653257
$10,462.23
in general payments reported to CMS, 2019-2025
20 companies · $4,491 in 2025
The $4,491 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $982 · 2022: $1,837 · 2023: $1,465 · 2024: $1,687 · 2025: $4,491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,255 · Travel and Lodging: $1,388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,255.30 |
| Travel and Lodging | $1,387.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $4,256.85 | 2021-2025 | General - Therapies, Emblem Mri S-Icd, Lux-Dx Insertable Cardiac Monitor |
| Abbott Laboratories | $2,419.17 | 2021-2025 | Aveir, Gallant, Jot Dx |
| Medtronic, INC. | $1,152.81 | 2021-2024 | Aurora Ev-Icd Mri Surescan, Linq II, Micra |
| Biotronik INC. | $525.79 | 2021-2025 | Biomonitor, Acticor 7 Vr-T Dx, Amvia Edge |
| Novartis Pharmaceuticals Corporation | $367.50 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $326.78 | 2021-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $179.51 | 2021-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $170.23 | 2023-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.51 | 2021-2025 | Jardiance |
| Pfizer INC. | $165.41 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $154.93 | 2021-2024 | Farxiga |
| Amgen INC. | $139.40 | 2021-2022 | |
| Kestra Medical Technology Services, INC. | $107.58 | 2024-2025 | Assure Wcd |
| Chiesi USA, INC. | $99.92 | 2021-2025 | Kengreal |
| Alnylam Pharmaceuticals INC. | $62.48 | 2025 | Amvuttra |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ebr Systems, INC. | $60.61 | 2025 | |
| Cardiva Medical, INC. | $39.42 | 2021-2022 | |
| Biosense Webster, INC. | $29.64 | 2021 | |
| Merck Sharp & Dohme LLC | $22.93 | 2022 | |
| Olympus America INC. | $11.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kena Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.